Key TakeawaysGilead signs royalty-free agreements with six global manufacturers to produce low-cost versions of Lenacapavir for HIV prevention and treatment.
The initiative targets...
MAT -
Key TakeawaysGilead has signed royalty-free licensing agreements with six generic manufacturers to produce low-cost versions of lenacapavir for HIV prevention in 120 high-incidence,...
Key TakeawaysLenacapavir demonstrated a 96% reduction in HIV infections compared to background HIV incidence in the Phase III PURPOSE 2 trial.
Lenacapavir’s twice-yearly...
Cholangitis, specifically primary biliary cholangitis (PBC), now has a promising new treatment option with the U.S. Food and Drug Administration (FDA) granting accelerated approval...
Gilead’s Twice-Yearly HIV Prevention Therapy Shows 100% Efficacy in Phase 3 Trial
Gilead Sciences, Inc. (Nasdaq: GILD) announced outstanding results from its pivotal Phase 3 PURPOSE 1 trial, which assessed the efficacy and safety of lenacapavir,...
Gilead and Elton John AIDS Foundation Expand HIV Efforts in Eastern Europe
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) have announced a significant five-year extension of their RADIAN®...
Healthcare innovations continue to reshape patient care, with recent advancements coming from Kite Pharma, a subsidiary of Gilead Sciences. Early last month, the company...
Promising Results for HIV Prevention: Gilead’s Lenacapavir Achieves 100% Efficacy
HIV prevention in cisgender women shows promising interim results from Gilead Sciences' Phase III PURPOSE 1 trial, which evaluates the efficacy of the twice-yearly...
FDA Approves Biktarvy for Pregnant People with HIV: Key Study Insights
Gilead Sciences recently disclosed that the FDA has expanded the label for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) to encompass its utilization in pregnant people living with...
